Pivikto 150MG Tablet, containing Alpelisib as its active ingredient, is a targeted therapy primarily used in the treatment of certain types of breast cancer, particularly hormone receptor-positive, HER2-negative breast cancer. This medication is designed for adult patients who have experienced disease progression following endocrine therapy. Each tablet contains 150 mg of Alpelisib, which works by inhibiting the PI3K (phosphoinositide 3-kinase) pathway, a crucial signaling pathway involved in cell growth and survival. By blocking this pathway, Pivikto helps to slow down or stop the growth of cancer cells, making it an essential component of a comprehensive cancer treatment plan. Pivikto is typically prescribed in combination with other medications, such as Fulvestrant, to enhance its effectiveness. The drug is available in a pack of 28 tablets, providing a month’s supply for patients undergoing treatment.